Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes

被引：3

作者：

Zupa, Margaret F. ^{[1
]}

Codario, Ronald A. ^{[1
,2
]}

Smith, Kenneth J. ^{[3
]}

机构：

[1] Univ Pittsburgh, Div Endocrinol & Metab, Pittsburgh, PA 15213 USA

[2] Vet Hlth Adm Pittsburgh Hlth Syst, Div Endocrinol, Pittsburgh, PA 15240 USA

[3] Univ Pittsburgh, Ctr Res Healthcare, Pittsburgh, PA 15213 USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 10卷 / 15期

关键词：

cost-effectiveness analysis; diabetes; GLP-1 receptor agonist; pharmacoeconomics; SGLT2; inhibitor; CONGESTIVE-HEART-FAILURE; GLP-1 RECEPTOR AGONISTS; CARDIOVASCULAR OUTCOMES; DISEASE; DAPAGLIFLOZIN; INHIBITORS; METFORMIN; UTILITY; PEOPLE;

D O I：

10.2217/cer-2021-0016

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: Perform a cost-effectiveness analysis of addition of subcutaneous semaglutide versus empagliflozin to usual treatment for patients with Type 2 diabetes and cardiovascular disease in US setting. Materials & methods: A Markov decision model estimated the impact of each strategy using cardiovascular complication rates based on EMPA-REG and SUSTAIN-6 trials. Modeled cohorts were followed for 3 years at 1-month intervals beginning at age 66. Results: Compared with empagliflozin, semaglutide resulted in cost of US$19,964 per quality-adjusted life-year gained. In one-way sensitivity analysis, only semaglutide cost >US$36.25/day (base case US$18.04) resulted in empagliflozin being preferred at a willingness-to-pay threshold of US$50,000/quality-adjusted life-year gained. Conclusion: For patients with Type 2 diabetes and cardiovascular disease, semaglutide is likely more cost-effective than empagliflozin added to usual treatment.

引用

页码：1133 / 1141

页数：9

共 42 条

[1]

Agency for Helathcare Research and Quality, 2020, HEALTHC COST UT PROJ

[2]

Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS111, DOI [10.2337/dc20-s010, 10.2337/dc20-S010]

[3] Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020 [J].

不详 .

DIABETES CARE, 2020, 43 :S98-S110

[4]

American Diabetes Association, 2020, DIABETES CARE, V43, pS151

[5] Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis [J].

Andreadis, Panagiotis ;

Karagiannis, Thomas ;

Malandris, Konstantinos ;

Avgerinos, Ioannis ;

Liakos, Aris ;

Manolopoulos, Apostolos ;

Bekiari, Eleni ;

Matthews, David R. ;

Tsapas, Apostolos .

DIABETES OBESITY & METABOLISM, 2018, 20 (09) :2255-2263

[6]

[Anonymous], 2020, Centersfor Disease Control and Prevention

[7]

[Anonymous], 2020, 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States

[8]

Arias E., 2017, National Vital Statistics Report

[9] Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment? [J].

Burgers, L. T. ;

Nauta, S. T. ;

Deckers, J. W. ;

Severens, J. L. ;

Redekop, W. K. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 176 (03) :980-987

[10] Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) [J].

Capehorn, M. S. ;

Catarig, A-M ;

Furberg, J. K. ;

Janez, A. ;

Price, H. C. ;

Tadayon, S. ;

Verges, B. ;

Marre, M. .

DIABETES & METABOLISM, 2020, 46 (02) :100-109

← 1 2 3 4 5 →